

Martin Lukas Sos

Status: Independent junior group leader
Address: Department of Translational Genomics
University Hospital Cologne
Weyertal 115b
50931 Cologne, Germany
Phone: +49 221 478 98771
E-mail: martin.sos@ucsf.edu
Day of Birth: 26th June 1979
Nationality: German

Education

2004 – 2007 Doctoral thesis: summa cum laude
2000 – 2007 Medical school at the University of Cologne, Germany

Professional and research experience

2012 – now Postdoctoral fellow at the Howard Hughes Medical Institute, Department of Cellular and Molecular Pharmacology, Shokat Lab, UCSF, San Francisco, CA, USA
2010 – 2012 Clinical Research fellow at the Center of Integrated Oncology, University of Cologne, Lung Cancer Group Jürgen Wolf, Germany
2007 – 2010 Postdoctoral fellow at the Max Planck Institute for Neurological Research Cologne, Thomas Lab, Cologne, Germany

Fellowships/Awards

2013 American Association of Cancer Research (AACR) Aflac scholar-in-training Award
2011 – 2013 Inter. Assoc. for the Study of Lung Cancer (IASLC), Young Investigator Award
2011 American Association of Cancer Research (AACR) Pezcoller scholar-in-training Award
2010 American Association of Cancer Research (AACR) Pezcoller scholar-in-training Award
2009 American Association of Cancer Research (AACR) scholar-in-training Award
2008 German Association of Hematology and Oncology (DGHO) award for outstanding medical thesis
2007 Max-Planck Institute – Young Investigator Fellowship
2005 – 2007 Köln Fortune Fellowship

Patents

P2126 PCT S3: A method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to dasatinib
US Patent 13/371,399: A method of treating lung cancer
US provisional Patent No. 61/530,847 and 61/606,296: Novel Chemotherapeutics

Selected publications

Sos ML,...Shokat KM.; Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.; *Cell Rep* Aug 2014

Sos ML (co-corresponding author),...Thomas RK.; A framework for identification of actionable cancer genome dependencies in small cell lung cancer.; *Proc Natl Acad Sci U S A*. Oct 2012

Weiss J*, **Sos ML* (co-first and co-corresponding author)**,...Thomas RK.; Frequent and Focal *FGFR1* Amplification Associates With Therapeutically Tractable *FGFR1* Dependency in Squamous-cell Lung Cancer.; *Sci Transl Med*. Dec 2010

Sos ML, ...Thomas RK; Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.; *Proc Natl Acad Sci U S A*. Oct 2009

Sos ML,...Thomas RK.; Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.; *J Clin Invest*. Jun 2009